Emanuela Amore

Dr. Emanuela Amore

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
EAEmanuela Amore
Emanuela Amore
VCVittoria Cenni
Vittoria Cenni
MPManuela Piazzi
Manuela Piazzi
MSMichele Signore
Michele Signore
GOGiulia Orlandi
Giulia Orlandi
Carla PalumboCarla Palumbo
Carla Palumbo
Galectin-3 (Gal-3) is a pleiotropic lectin produced by most cell types, which regulates multiple cellular processes in various tissues. In bone, depending on its cellular localization, Gal-3 has a dual and opposite role. If, on the one hand, intracellular Gal-3 promotes bone formation, on the other, its circulating form affects bone remodeling, antagonizing osteoblast differentiation and increasing osteoclast activity. From an analysis of the secretome of cultured differentiating myoblasts, we interestingly found the presence of Gal-3. After that, we confirmed that Gal-3 was expressed and released in the extracellular environment from myoblast cells during their differentiation into myotubes, as well as after mechanical strain. An in vivo analysis revealed that Gal-3 was triggered by trained exercise and was specifically produced by fast muscle fibers. Speculating a role for this peptide in the muscle-to-bone cross talk, a direct co-culture in vitro system, simultaneously combining media that were obtained from differentiated myoblasts and osteoblast cells, confirmed that Gal-3 is a mediator of osteoblast differentiation. Molecular and proteomic analyses revealed that the secreted Gal-3 modulated the biochemical processes occurring in the early phases of bone formation, in particular impairing the activity of the STAT3 and PDK1/Akt signaling pathways and, at the same time, triggering that one of Notch. Circulating Gal-3 also affected the expression of the most common factors involved in osteogenetic processes, including BMP-2, -6, and -7. Intriguingly, Gal-3 was able to interfere with the ability of differentiating osteoblasts to interact with the components of the extracellular bone matrix, a crucial condition required for a proper osteoblast differentiation. All in all, our evidence lays the foundation for further studies to present this lectin as a novel myokine involved in muscle-to-bone crosstalk.

12 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LGLaura Gambari
Laura Gambari
Eleonora PagnottaEleonora Pagnotta
Eleonora Pagnotta
LULuisa Ugolini
Luisa Ugolini
LRLaura Righetti
Laura Righetti
EAEmanuela Amore
Emanuela Amore
FGFrancesco Grassi
Francesco Grassi
Background/Objectives: Crude extracts from the Brassica genus have recently emerged as promising phytochemicals for preventing bone loss. While the most documented evidence suggests that their general biological activity is due to glucosinolates’ (GLSs’) hydrolysis products, the direct activity of GLSs is beginning to be uncovered. However, the contribution of GLSs to the bone-sparing activity of crude Brassicaceae extracts has seldom been addressed. Here, we aimed to gain insights into this gap by studying in the same in vitro model of human osteogenesis the effect of two Brassica seed extracts (Eruca sativa and Lepidium sativum) obtained from defatted seed meals, comparing them to the isolated GLSs most represented in their composition, glucoerucin (GER) and glucotropaeolin (GTL), for Eruca sativa and Lepidium sativum, respectively. Methods: Osteogenic differentiation of human mesenchymal stromal cells (hMSCs) was assessed by alizarin red staining assay and real-time PCR, respectively, evaluating mineral apposition and mRNA expression of specific osteogenic genes. Results: Both Brassica extracts and GLSs increased the osteogenic differentiation, indicating that the stimulating effect of Brassica extracts can be at least partially attributed to GLSs. Moreover, these data extend previous evidence of the effect of unhydrolyzed glucoraphanin (GRA) on osteogenesis to other types of GLSs: GER and GTL. Notably, E. sativa extract and GTL induced higher osteogenic stimulation than Lepidium sativum extract and GER, respectively. Conclusions: Overall, this study expands the knowledge on the possible application of Brassica-derived bioactive molecules as natural alternatives for the prevention and treatment of bone-loss pathologies.

22 April 2026 in Gels
Verified
Journal Article
Open access
PDF file
CCCarola Cavallo
Carola Cavallo
EAEmanuela Amore
Emanuela Amore
SCSara Carpentieri
Sara Carpentieri
Livia RosetiLivia Roseti
Livia Roseti
The increase in older adults and active lifestyles has made chondral and osteochondral lesions common in the population, making them one of the central challenges in orthopedics. Although hydrogel-based regenerative medicine offers an encouraging therapeutic option for these lesions, important obstacles still prevent these therapies from reaching the clinic. In view of these factors, we adopted a risk-based approach for this review, in line with the current legislative requirements in clinical translation and clinical trials. We identified the factors that could undermine patient safety or lead to poor outcomes. Then, we outlined solutions to remedy these problems that integrate hydrogel technology, clinical/pharmaceutical/surgical protocols, and post-operative follow-up. Upcoming studies should give priority to the development of hydrogel scaffolds modified to mimic cartilage’s mechanical and physicochemical properties, together with patient-specific features. Other crucial characteristics are host-tissue integration, long-lasting cartilage tissue regeneration, and a positive outcome. In parallel, to scale complex and costly innovations, efforts should focus on a harmonized, simplified legislative landscape, optimized standards, and established follow-up protocols. Getting through this “valley of death” between research and innovation is strategic for reaching the clinics and the largest number of patients.

Verified
Journal Article
Open access
PDF file
Livia RosetiLivia Roseti
Livia Roseti
GBGiorgia Borciani
Giorgia Borciani
EAEmanuela Amore
Emanuela Amore
Brunella GrigoloBrunella Grigolo
Brunella Grigolo
The management of rheumatic diseases has noticeably changed in recent years with the development of targeted therapeutic agents, namely, biological disease-modifying antirheumatic drugs. Identifying essential signaling pathways and factors crucial for the development and progression of these diseases remains a significant challenge. Therapy could be used to delay the onset or reduce harm. The endocannabinoid system’s presence within the synovium can be identified as a suggested target for therapeutic interventions due to its role in modulating pain, inflammation, and joint metabolism. This review brings together the most pertinent information concerning the actions of the endocannabinoid system present in inflamed synovial tissue and its interaction with phytocannabinoids and synthetic cannabinoids, which can be used from a therapeutic perspective to minimize the inflammatory and pain processes typical of osteoarthritis and rheumatoid arthritis.

10 December 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
GDGiovanna Desando
Giovanna Desando
LGLaura Gambari
Laura Gambari
EAEmanuela Amore
Emanuela Amore
GBGiorgia Borciani
Giorgia Borciani
SCSara Carpentieri
Sara Carpentieri
Livia RosetiLivia Roseti
Livia Roseti
Osteoarthritis is a common joint disease mainly characterized by inflammation and pain. Some promising approaches are aimed at combating the general mechanisms of osteoarthritis development and progression by targeting specific molecules. Although scientific and clinical communities remain skeptical regarding the efficacy of nutrition in managing human diseases, several products have been recognized as capable of improving health conditions and counteracting specific chronic and inflammatory musculoskeletal disorders such as osteoarthritis. The aim of this narrative review is to present the results obtained by a search through electronic databases on the effect of glucosinolates and their breakdown products, in particular isothiocyanates, in both the prevention and complementary therapy for osteoarthritis. Even if we found a few studies on this topic, some preclinical studies demonstrated an active role of these compounds in reducing inflammation, oxidative stress, and apoptosis. A beneficial effect of a diet rich in glucoraphanin, a glucosinolate derivative, has been associated with a lower risk of developing osteoarthritis in a proof-of-principle trial. To further advance this topic, it is essential to conduct additional preclinical studies to address existing research gaps, alongside more rigorous clinical investigations, especially long-term randomized controlled trials. These efforts should focus on determining the most effective type of glucosinolate and relative metabolites in counteracting osteoarthritis progression and identifying their dose–response behavior to assess both benefits and side effects associated with their oral intake.

Verified
Journal Article
Open access
PDF file
LGLaura Gambari
Laura Gambari
EAEmanuela Amore
Emanuela Amore
Livia RosetiLivia Roseti
Livia Roseti
SCSara Carpentieri
Sara Carpentieri
CRClaudio Ripamonti
Claudio Ripamonti
FGFrancesco Grassi
Francesco Grassi
Postmenopausal osteoporosis is an age-related condition in which estrogen deficiency drives low-grade inflammation and oxidative stress, disrupting the homeostatic balance between bone formation and resorption. Since osteopenia represents a critical intermediate stage, preventive strategies are essential to mitigate its progression. Preclinical studies suggest that hydrogen sulfide (H2S), a gaseous mediator with antioxidant properties, protects bone metabolism by supporting osteoblast function and suppressing osteoclast activity. Building on this evidence, we conducted the first exploratory clinical trial assessing the effects of inhalation therapy with sulfurous mineral waters on systemic biomarkers in postmenopausal women with osteopenia. Thirty-eight eligible participants underwent a daily inhalation of sulfurous waters (14.6 mg/L sulfide) for 12 consecutive days. Biomarkers of oxidative stress, inflammation, and bone turnover were assessed at baseline, immediately post-treatment, and five days after cessation in the serum of patients. The treatment was well tolerated and did not cause any early adverse effect. Serum H2S levels, measured in a subset of participants, significantly increased, confirming systemic bioavailability. Sulfurous water inhalation induced a marked change in oxidative stress, with malondialdehyde levels declining by up to 37% from baseline. Pro-inflammatory cytokines, particularly IL-8 and MIP-1α, were significantly decreased (up to 50–70%) at the end of the treatment. Reference bone turnover markers P1NP and CTX-1 did not show significant changes; however, BALP exhibited a significant increase, suggesting the activation of pathways linked to biomineralization. These findings provide preliminary human evidence that inhaled sulfurous waters enhance systemic H2S bioavailability and modulate redox and inflammatory pathways associated with bone remodeling in osteopenic women, supporting the rationale for further controlled pharmacodynamic investigations evaluating the potential of H2S in bone health.